Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $48
Edgewise Therapeutics To Host Webcast Event To Discuss Top-Line Data From Phase 1 Trial In Healthy Subjects And Phase 2 CIRRUS-HCM Trial In Patients With Obstructive HCM On Thursday, September 19 at 8:30 Am ET
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $32
Edgewise Jumps Ahead of "Key Stock-moving Event"
Edgewise Therapeutics Is Maintained at Outperform by RBC Capital
Edgewise Therapeutics Price Target Maintained With a $32.00/Share by RBC Capital
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long